Panacea Biotech share price has plunged 5% and is presently trading at Rs 273.1.
Meanwhile, the BSE HEALTHCARE index is at 44,093.6 (down 0.2%).
Among the top losers in the BSE HEALTHCARE index today are ALKEM LABORATORIES (down 1.2%) and LAURUS LABS (down 1.2%).
Abbott India (up 1.4%) and GRANULES INDIA (up 1.2%) are among the top gainers today.
Over the last one year, Panacea Biotech has moved up from Rs 160.5 to Rs 273.1, registering a gain of Rs 112.6 (up 70.1%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,800.9 to 44,093.6, registering a gain of 58.6% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 186.7%), SUVEN PHARMACEUTICALS (up 124.3%) and Glenmark Pharma (up 113.4%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 85,341.5 (up 0.2%).
The top gainers among the BSE Sensex today are Maruti Suzuki (up 2.5%) and Tata Motors (up 1.7%). The most traded stocks in the BSE Sensex are Tata Steel and NTPC.
In the meantime, NSE Nifty is at 26,049.1 (up 0.2%). Maruti Suzuki and Tata Motors are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 66,023.7 to 85,341.5, registering a gain of 19,317.8 points (up 29.3%).
Panacea Biotech net profit fell 244.6% YoY to Rs -159 million for the quarter ended June 2024, compared to a profit of Rs 110 million a year ago. Net sales declined 10.4% to Rs 1,157 million during the period as against Rs 1,292 million in April-June 2023.
For the year ended March 2023, Panacea Biotech reported 103.1% decrease in net profit to Rs -337 million compared to net profit of Rs 10,783 million during FY22. Revenue of the company fell 30.4% to Rs 4,599 million during FY23.
The current Price to earnings ratio of Panacea Biotech, based on rolling 12 month earnings, stands at -59.0.
Equitymaster requests your view! Post a comment on "Panacea Biotech Plunges 5%; BSE HEALTHCARE Index Down 0.2%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!